{"id":"simvastatin-ezetimibe","safety":{"commonSideEffects":[{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Simvastatin is an HMG-CoA reductase inhibitor that decreases endogenous cholesterol production in the liver. Ezetimibe selectively inhibits cholesterol absorption in the small intestine by blocking the Niemann-Pick C1-like 1 (NPC1L1) transporter. The combination provides complementary mechanisms to achieve greater LDL-C reduction than either agent alone.","oneSentence":"Simvastatin inhibits cholesterol synthesis while ezetimibe blocks dietary cholesterol absorption, together reducing LDL cholesterol levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:37:49.085Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia and dyslipidemia"},{"name":"Reduction of cardiovascular risk in patients with elevated cholesterol"}]},"trialDetails":[{"nctId":"NCT06437574","phase":"PHASE2","title":"Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2024-07-16","conditions":"Prostate Cancer","enrollment":140},{"nctId":"NCT07307989","phase":"PHASE2","title":"Early Statin-Ezetimibe Combination vs. Statin Monotherapy in Stroke With Atherosclerosis","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2025-08-01","conditions":"Ischemic Stroke, Hypercholesteremia","enrollment":300},{"nctId":"NCT06501443","phase":"PHASE4","title":"LATAM LOWERS LDL-C","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-02-11","conditions":"Hypercholesterolaemia","enrollment":520},{"nctId":"NCT06858332","phase":"","title":"Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-04-15","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":2382},{"nctId":"NCT04638400","phase":"PHASE4","title":"Anti-inflammatory Effects of Simvastatin","status":"TERMINATED","sponsor":"paresh Dandona","startDate":"2017-05-01","conditions":"Inflammation, Atherosclerosis, Hypercholesterolemia","enrollment":10},{"nctId":"NCT01414192","phase":"","title":"A Study to Design a Model Cohort for Analysis of Dyslipidemia (MK-0653A-204)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-11-15","conditions":"Dyslipidemia, Hypercholesterolemia","enrollment":3215},{"nctId":"NCT00092651","phase":"PHASE3","title":"A Study of MK0653A (Ezetimibe (+) Simvastatin) in Patients With Hypercholesterolemia (0653A-038)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-09","conditions":"Hypercholesterolemia","enrollment":1398},{"nctId":"NCT00541697","phase":"PHASE3","title":"Eze/Simva Switch Study in Diabetics (0653A-807)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-01-19","conditions":"Diabetes Mellitus, Type 2","enrollment":648},{"nctId":"NCT00652717","phase":"PHASE4","title":"Study To Assess The Efficacy Of A Cholesterol Lowering Drug On Top Of Statins In Patients After Myocardial Infarction (MI)(0653A-150)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-02-01","conditions":"Cardiovascular Disorder","enrollment":280},{"nctId":"NCT00551876","phase":"PHASE3","title":"Study Evaluating the Efficacy and Safety of Simvastatin Alone Compared With Simvastatin Plus Ezetimibe in Type 2 Diabetic Patients (0653-021)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-12","conditions":"Diabetes Mellitus, Type 2","enrollment":214},{"nctId":"NCT00651560","phase":"PHASE3","title":"Vytorin As Strategy To Reduce Dislipidemia In Adults (0653A-148)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-11-01","conditions":"Hyperlipidemia","enrollment":167},{"nctId":"NCT00551447","phase":"PHASE3","title":"A Study Comparing Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Patients at Risk for Heart Disease (0653-023)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-01","conditions":"Coronary Disease","enrollment":616},{"nctId":"NCT00093899","phase":"PHASE3","title":"A Study to Evaluate an Investigational Drug in Patients With Mixed Hyperlipidemia (0653A-071)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-11","conditions":"Hyperlipidemia, Hypercholesterolemia, Hypertriglyceridemia","enrollment":611},{"nctId":"NCT00650819","phase":"PHASE3","title":"Comparison of Ezetimibe Plus Simvastatin Versus Ezetimibe or Simvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03757)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-06-01","conditions":"Hypercholesterolemia","enrollment":240},{"nctId":"NCT00552097","phase":"PHASE3","title":"Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery (ENHANCE)(P02578)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-06-01","conditions":"Atherosclerosis, Hypercholesterolemia, Hyperlipoproteinemia Type II","enrollment":720},{"nctId":"NCT00092664","phase":"PHASE3","title":"An Extension Study of An Investigational Drug in Patients With Hypercholesterolemia (0653A-038)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-01","conditions":"Hypercholesterolemia","enrollment":1104},{"nctId":"NCT00090298","phase":"PHASE3","title":"Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Drugs in Patients With Elevated Cholesterol Levels (0653A-058)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-04","conditions":"Hypercholesterolemia","enrollment":2815},{"nctId":"NCT00650663","phase":"PHASE4","title":"Ezetimibe Plus Simvastatin Versus Simvastatin Alone in African-American Subjects With Primary Hypercholesterolemia (P03377)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-10-01","conditions":"Hypercholesterolemia, Atherosclerosis","enrollment":247},{"nctId":"NCT00092716","phase":"PHASE3","title":"Comparing an Investigational Medication Versus an Approved Medication in Reducing Cholesterol Levels (0653-025)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-05","conditions":"Hypercholesterolemia","enrollment":655},{"nctId":"NCT00132717","phase":"PHASE3","title":"A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-01-01","conditions":"Hypercholesterolemia","enrollment":450},{"nctId":"NCT00157911","phase":"PHASE3","title":"A Study to Evaluate Ezetimibe in Korean Patients With Primary Hypercholesterolemia (0653-042)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-12","conditions":"Hypercholerolemia","enrollment":136},{"nctId":"NCT00653835","phase":"PHASE4","title":"Ezetimibe Plus Simvastatin Versus Simvastatin in Untreated Subjects With High Cholesterol (P03435)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-09-01","conditions":"Hypercholesterolaemia, Atherosclerosis","enrollment":153},{"nctId":"NCT00110435","phase":"PHASE3","title":"A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-05","conditions":"Type 2 Diabetes Mellitus, Hypercholesterolemia","enrollment":1229},{"nctId":"NCT00652301","phase":"PHASE3","title":"A Research Study to Evaluate MK0653 (Ezetimibe) and Simvastatin, Given Together and Alone, on Intestinal Absorption of Cholesterol (0653-050)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-07","conditions":"Cholesterol","enrollment":40},{"nctId":"NCT00651274","phase":"PHASE4","title":"Comparison of Co-administration of Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Primary Hypercholesterolemia (P03476)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-04-01","conditions":"Atherosclerosis, Hypercholesterolemia, Coronary Heart Disease","enrollment":144},{"nctId":"NCT00092612","phase":"PHASE3","title":"Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-802)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-05","conditions":"Hypercholesterolemia, Coronary Disease","enrollment":372},{"nctId":"NCT00092599","phase":"PHASE3","title":"Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-801)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-02","conditions":"Hypercholesterolemia, Coronary Disease","enrollment":410},{"nctId":"NCT00166530","phase":"PHASE4","title":"EASEGO Study: Doubling of Atorvastatin/Simvastatin or INEGY in Patients With Hypercholesterolemia and Coronary Artery Disease(CAD)(0653A-089)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-11","conditions":"Atherosclerosis","enrollment":367},{"nctId":"NCT00090168","phase":"PHASE3","title":"Cholesterol Lowering Level of MK0653A+Simvastatin in Patients With Hypercholesterolemia and Atherosclerotic or Coronary Vascular Disease (0653A-806)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-01-27","conditions":"Hypercholesterolemia, Atherosclerotic Disease, Coronary Disease","enrollment":435},{"nctId":"NCT00651391","phase":"PHASE3","title":"Effect of Ezetimibe Plus Simvastatin on Flow-Mediated Brachial Artery Vasoactivity in Subjects With Primary Hypercholesterolemia (Study P03336)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2003-10-01","conditions":"Hypercholesterolemia, Atherosclerosis","enrollment":28},{"nctId":"NCT00395603","phase":"PHASE3","title":"Vytorin Treating Uncontrolled Lipids (VyTUL) Study (0653A-122)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2006-09","conditions":"Cardiovascular Diseases, Diabetes Mellitus","enrollment":550},{"nctId":"NCT00202878","phase":"PHASE3","title":"IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-10-17","conditions":"Hypercholesterolemia, Myocardial Infarction","enrollment":18144},{"nctId":"NCT00157924","phase":"PHASE4","title":"Ezetimibe (+) Simvastatin vs. Atorvastatin Comparative Study in DM or Metabolic Syndrome Patients (0653A-093)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-11","conditions":"Hypercholesterolemia","enrollment":190},{"nctId":"NCT00442897","phase":"PHASE4","title":"Vytorin (10/20 Or 10/40) Compared to Atorvastatin (10 mg or 20 mg) in Patients With Coronary Artery Disease (0653A-126)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-09","conditions":"Hypercholesterolemia","enrollment":229},{"nctId":"NCT00654628","phase":"PHASE4","title":"Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients (0653A-172)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-08-01","conditions":"Hypercholesterolemia","enrollment":173},{"nctId":"NCT00166504","phase":"PHASE4","title":"Ezetimibe Plus (+) Simvastatin Versus Atorvastatin Comparative Study (0653A-092)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-10","conditions":"Hypercholesterolemia","enrollment":203},{"nctId":"NCT00423579","phase":"PHASE4","title":"The Effects of Ezetimibe/Simvastatin 10/20 mg Versus Simvastatin 40 mg in High Cholesterol and Coronary Heart Disease Study (P04039AM2)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-07-01","conditions":"Hypercholesterolemia, Coronary Disease","enrollment":120},{"nctId":"NCT00653523","phase":"PHASE3","title":"Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercholesterolemia (P05457)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-12-01","conditions":"Hypercholesterolemia","enrollment":151},{"nctId":"NCT00496730","phase":"PHASE3","title":"A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea (0653A-129)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-07","conditions":"Hypercholesterolemia","enrollment":256},{"nctId":"NCT00535405","phase":"PHASE3","title":"A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-11","conditions":"Hypercholesterolemia","enrollment":1289},{"nctId":"NCT00409773","phase":"PHASE3","title":"Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-01","conditions":"Hypercholesterolemia, Metabolic Syndrome","enrollment":1143},{"nctId":"NCT00782184","phase":"PHASE3","title":"Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-11","conditions":"Hypercholesterolemia","enrollment":250},{"nctId":"NCT00462748","phase":"PHASE3","title":"A Study to Determine the Number of Patients Who Reach Optimal Cholesterol Levels on Each of Three Different Treatments (0653A-121)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-03","conditions":"Hypercholesterolemia","enrollment":786},{"nctId":"NCT00092677","phase":"PHASE3","title":"An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-01","conditions":"Aortic Stenosis","enrollment":1873},{"nctId":"NCT00479713","phase":"PHASE3","title":"A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Patients With High Cholesterol and With High Cardiovascular Risk (0653A-809)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-02-01","conditions":"Hypercholesterolemia","enrollment":618},{"nctId":"NCT00271817","phase":"PHASE3","title":"To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-12","conditions":"Hypercholesterolemia","enrollment":1220},{"nctId":"NCT00862251","phase":"PHASE3","title":"Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2009-04","conditions":"Cardiovascular Disorder, Diabetes Mellitus","enrollment":808},{"nctId":"NCT03882905","phase":"PHASE3","title":"A Study of SCH 58235 (Ezetimibe) When Added to Ongoing Therapy With a Statin in Participants With Primary Hypercholesterolemia, Known Coronary Heart Disease, or Multiple Cardiovascular Risk Factors (P02173)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-01-31","conditions":"Primary Hypercholesterolemia","enrollment":769},{"nctId":"NCT00092690","phase":"PHASE3","title":"MK0653A (Ezetimibe (+) Simvastatin) Compared to an Approved Drug (Atorvastatin) for the Treatment of High Cholesterol (0653A-051)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-06","conditions":"Hypercholesterolemia","enrollment":1902},{"nctId":"NCT03884452","phase":"PHASE3","title":"Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-05-03","conditions":"Familial Hypercholesterolemia","enrollment":50},{"nctId":"NCT01420328","phase":"NA","title":"To Study the Effect of Vytorin on Intracellular Lipid and Inflammation in Obese Subjects","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2011-05-01","conditions":"Inflammation","enrollment":20},{"nctId":"NCT00988364","phase":"PHASE4","title":"Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome.","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2007-03","conditions":"Metabolic Syndrome","enrollment":30},{"nctId":"NCT03510884","phase":"PHASE3","title":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-05-31","conditions":"Hypercholesterolaemia","enrollment":153},{"nctId":"NCT02534376","phase":"EARLY_PHASE1","title":"Cellular Effect of Cholesterol-Lowering Prior to Prostate Removal","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2015-09","conditions":"Prostate Cancer","enrollment":63},{"nctId":"NCT05613400","phase":"PHASE4","title":"Statin and Bone Health","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2022-04-13","conditions":"Diabetes Mellitus, Type 2","enrollment":240},{"nctId":"NCT01763866","phase":"PHASE3","title":"LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-01-15","conditions":"Hyperlipidemia","enrollment":2067},{"nctId":"NCT01047501","phase":"PHASE3","title":"Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":702},{"nctId":"NCT01047683","phase":"PHASE3","title":"Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":229},{"nctId":"NCT01492361","phase":"PHASE3","title":"A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2011-11","conditions":"Cardiovascular Diseases","enrollment":8179},{"nctId":"NCT02476006","phase":"PHASE3","title":"Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-06-23","conditions":"Hypercholesterolemia","enrollment":998},{"nctId":"NCT01587235","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Vytorin Versus Standard Treatment of Other Statins in Moderate, Moderately High and High Risk Participants (MK-0653A-406)","status":"WITHDRAWN","sponsor":"Organon and Co","startDate":"2013-03","conditions":"Dyslipidemia","enrollment":""},{"nctId":"NCT00652444","phase":"PHASE4","title":"Effect Of Ezetimibe Coadministration With Simvastatin In A Middle Eastern Population: A Prospective, Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial (0653-151)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-09","conditions":"Hypercholesterolemia","enrollment":120},{"nctId":"NCT03885921","phase":"PHASE3","title":"Safety and Tolerability Study of Ezetimibe (SCH 058235/MK-0653) Plus Atorvastatin or Simvastatin in Homozygous Familial Hypercholesterolemia (P01417/MK-0653-019)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-10-25","conditions":"Hypercholesterolemia","enrollment":44},{"nctId":"NCT00651014","phase":"PHASE4","title":"Ezetimibe Plus Simvastatin Versus Simvastatin in Patients With Hypercholesterolemia and Coronary Risk Factors (P03405)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2004-01","conditions":"Hypercholesterolemia, Atherosclerosis","enrollment":82},{"nctId":"NCT00652431","phase":"PHASE1","title":"Assessment of Interaction Between Vytorin and Niaspan in Healthy Subjects (P04955AM2)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-05","conditions":"Hypercholesterolemia, Hyperlipidemia","enrollment":18},{"nctId":"NCT00413972","phase":"PHASE3","title":"Effects of Vytorin Versus Placebo in Subjects With Primary Hypercholesterolemia (Study P04420)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-04","conditions":"Hypercholesterolemia","enrollment":392},{"nctId":"NCT01070966","phase":"","title":"Vytorin Reexamination Study (0653A-174)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-07","conditions":"Primary Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH)","enrollment":2089},{"nctId":"NCT00423488","phase":"PHASE3","title":"Ezetimibe and Simvastatin in Primary Hypercholesterolemia, Diabetes Mellitus Type 2, and Coronary Heart Disease (COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-07-12","conditions":"Hypercholesterolemia, Diabetes Mellitus, Type 2, Coronary Disease","enrollment":93},{"nctId":"NCT00730132","phase":"","title":"Observational Study of Approaches to Lipid-Lowering Therapy in Russian Patients With Coronary Heart Disease <<Treat to Goal>> (Study P05464)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-01","conditions":"Coronary Heart Disease, Hypercholesterolemia","enrollment":712},{"nctId":"NCT01077830","phase":"","title":"An Observational Follow-Up Study of the Incidence of Cancer and Mortality in Patients From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Trial (MK-0653A-043-10)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2010-03","conditions":"Cancer","enrollment":1392},{"nctId":"NCT00724477","phase":"","title":"Retrospective Evaluation of the Percentage of Subjects Who Have Reached Their LDL-C Objectives After Treatment With INEGY (Study P05103)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-10","conditions":"Primary Hypercholesterolemia","enrollment":1663},{"nctId":"NCT00652327","phase":"PHASE4","title":"Comparison of Ezetimibe Added to Ongoing Statin Therapy Versus Doubling the Dose of Statin in the Treatment of Hypercholesterolemia (P04355)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-12","conditions":"Hypercholesterolemia","enrollment":83},{"nctId":"NCT00909389","phase":"","title":"Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Vytorin (Ezetimibe + Simvastatin) Tablet Among Filipino Patients (Study P05647)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-11","conditions":"Hypercholesterolemia","enrollment":4748},{"nctId":"NCT00129402","phase":"PHASE3","title":"Effects of Ezetimibe With Simvastatin in the Therapy of Adolescents With HeFH (Study P02579)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-08","conditions":"Hypercholesterolemia","enrollment":248},{"nctId":"NCT05080140","phase":"","title":"Investigate the Effect of Ezetimibe, Simvastatin, and Omega 3- Fatty Acids on Dyslipidemia Patients: a Pharmacokinetics Based Study","status":"UNKNOWN","sponsor":"Misr University for Science and Technology","startDate":"2019-06-01","conditions":"Hyperlipidemia; Mixed","enrollment":3},{"nctId":"NCT03355027","phase":"NA","title":"Investigating the Lowest Threshold of Vascular Benefits From LDL Cholesterol Lowering in Patients With Stable CV Disease","status":"UNKNOWN","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2017-11-30","conditions":"Atherosclerosis, Cardiovascular Diseases","enrollment":60},{"nctId":"NCT04829149","phase":"","title":"Statin Monotherapy and Rosuzet Tab.(Rosuvastatin/Ezetimibe) Administration in Patients With Dyslipidemia in Korea","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2016-06-14","conditions":"Dyslipidemias","enrollment":5717},{"nctId":"NCT01035320","phase":"PHASE4","title":"Platelet Function in Diabetic Patients With and Without Renal Impairment, and the Effects of Lipid Lowering Treatment","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2006-01","conditions":"Diabetes Mellitus, Impaired Renal Function","enrollment":39},{"nctId":"NCT03510715","phase":"PHASE3","title":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-08-31","conditions":"Hypercholesterolemia","enrollment":18},{"nctId":"NCT00477204","phase":"PHASE2","title":"Clinical Trial of Zocor (Simvastatin) and Vytorin (Ezetimibe/Simvastatin) in Adolescents With Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2007-05","conditions":"Type 1 Diabetes Mellitus, Dyslipidemia","enrollment":9},{"nctId":"NCT00879710","phase":"NA","title":"Effect of Diabetes Mellitus on Cholesterol Metabolism","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2008-08","conditions":"Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Hypercholesterolemia","enrollment":57},{"nctId":"NCT00687076","phase":"PHASE4","title":"Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2004-04","conditions":"Peripheral Arterial Disease","enrollment":102},{"nctId":"NCT01420549","phase":"PHASE3","title":"Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia","status":"COMPLETED","sponsor":"Ache Laboratorios Farmaceuticos S.A.","startDate":"2013-03","conditions":"Hypercholesterolemia, Dyslipidemia","enrollment":129},{"nctId":"NCT00819403","phase":"PHASE4","title":"Simvastatin With or Without Ezetimibe and Atherothrombotic Biomarker Assessment","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2009-01","conditions":"Metabolic Syndrome","enrollment":15},{"nctId":"NCT02715726","phase":"PHASE3","title":"Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-27","conditions":"Hypercholesterolemia","enrollment":615},{"nctId":"NCT01890967","phase":"PHASE2","title":"A Study of LY3015014 in Participants With High Cholesterol","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-06","conditions":"Hypercholesterolemia","enrollment":527},{"nctId":"NCT04061824","phase":"PHASE4","title":"Clinical Study to Evaluate Adherence Improvement Fixed-dose Combination of Olostar Tab. in Patients With Hypertension and Dyslipidemia","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2016-05-24","conditions":"Hypertension, Dyslipidemias","enrollment":150},{"nctId":"NCT03543774","phase":"PHASE4","title":"Lipid-lowering Therapies in Vietnamese Chronic Kidney Disease Population","status":"UNKNOWN","sponsor":"Hue University of Medicine and Pharmacy","startDate":"2018-06-15","conditions":"Hypercholesterolemia, Chronic Kidney Diseases","enrollment":30},{"nctId":"NCT03771053","phase":"NA","title":"The Effect of Simvastatin Combined With Ezetimibe in Patients With Stable Angina and Diabetes","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2018-01-01","conditions":"Coronary Heart Disease","enrollment":240},{"nctId":"NCT02304926","phase":"NA","title":"Effects of Simvastatin and Ezetimibe on Cardiovascular Risk Markers in Patients With Dyslipidemia","status":"COMPLETED","sponsor":"Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana","startDate":"2009-01","conditions":"Dyslipidemia","enrollment":42},{"nctId":"NCT00359281","phase":"PHASE2","title":"Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents","status":"COMPLETED","sponsor":"Aegerion Pharmaceuticals, Inc.","startDate":"2006-03","conditions":"Healthy","enrollment":125},{"nctId":"NCT02378064","phase":"PHASE4","title":"Comparison of Fimasartan Versus Amlodipine Therapy on Carotid PlaquE Inflammation","status":"COMPLETED","sponsor":"CHEOL WHAN LEE, M.D., Ph.D","startDate":"2015-05","conditions":"Inflammation Plaque, Atherosclerotic, Coronary Disease, Renin-Angiotensin System","enrollment":50},{"nctId":"NCT00127218","phase":"PHASE3","title":"High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2003-09","conditions":"Atherosclerosis, Cardiovascular Disease","enrollment":145},{"nctId":"NCT00587678","phase":"NA","title":"Comprehensive Magnetic Resonance of Peripheral Arterial Disease","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2006-01","conditions":"Peripheral Artery Disease","enrollment":85},{"nctId":"NCT00385658","phase":"PHASE4","title":"Efficacy of Fluvastatin and Fenofibrate in Comparison to Simvastatin and Ezetimibe in Patients With Metabolic Syndrome","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-08","conditions":"Dyslipidemia","enrollment":75},{"nctId":"NCT01644188","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-08","conditions":"Hypercholesterolemia","enrollment":720},{"nctId":"NCT02547402","phase":"PHASE1","title":"A Study of the PK Interaction of CXA-10 With Pravastatin and Vytorin® in Healthy Males","status":"COMPLETED","sponsor":"Complexa, Inc.","startDate":"2015-12","conditions":"Acute Kidney Injury","enrollment":10},{"nctId":"NCT00120289","phase":"PHASE3","title":"Niacin Plus Statin to Prevent Vascular Events","status":"TERMINATED","sponsor":"Axio Research. LLC","startDate":"2005-09","conditions":"Cardiovascular Diseases, Heart Diseases, Cerebrovascular Accident","enrollment":3414},{"nctId":"NCT02548936","phase":"EARLY_PHASE1","title":"Efficacy and Safety of Simvastatin-ezetimibe Combination Therapy Among Patients With SLE","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2015-04","conditions":"Atherosclerosis","enrollment":30},{"nctId":"NCT00738296","phase":"PHASE4","title":"Vytorin on Carotid Intima-media Thickness and Overall Rigidity","status":"COMPLETED","sponsor":"Hospital Universitario 12 de Octubre","startDate":"2005-04","conditions":"Cardiovascular Diseases","enrollment":90}],"_emaApprovals":[],"_faersSignals":[{"count":12,"reaction":"BLOOD GLUCOSE INCREASED"},{"count":11,"reaction":"HYPOGLYCAEMIA"},{"count":10,"reaction":"DYSPNOEA"},{"count":9,"reaction":"DIZZINESS"},{"count":8,"reaction":"NAUSEA"},{"count":7,"reaction":"CHEST PAIN"},{"count":7,"reaction":"DRUG INTERACTION"},{"count":7,"reaction":"FATIGUE"},{"count":7,"reaction":"HYPOTENSION"},{"count":6,"reaction":"ATRIAL FIBRILLATION"}],"_approvalHistory":[],"publicationCount":150,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Simvastatin/Ezetimibe (Zetia)","Vytorin"],"phase":"marketed","status":"active","brandName":"Simvastatin/Ezetimibe","genericName":"Simvastatin/Ezetimibe","companyName":"dr.Frank L.J. Visseren","companyId":"dr-frank-l-j-visseren","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Simvastatin inhibits cholesterol synthesis while ezetimibe blocks dietary cholesterol absorption, together reducing LDL cholesterol levels. Used for Hypercholesterolemia and dyslipidemia, Reduction of cardiovascular risk in patients with elevated cholesterol.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}